Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation

Mitra, Anirban P.; Fairey, Adrian; Skinner, Eila C.; Boorjian, Stephen A.; Frank, Igor; Schoenberg, Mark; Bivalacqua, Trinity J.; Hyndman, M. Eric; Reese, Adam C.; Steinberg, Gary D.; Large, Michael C.; Kaa, Christina A. Hulsbergen‐van de; Bruins, Harman Max; Daneshmand, Siamak

doi:10.1016/j.urolonc.2018.10.013

Cited by 22 publications

(16 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concomitant VMs can be characterized by a highly metastatic potential. As to micropapillary variant, a large multi-institutional cohort study demonstrated that micropapillary variant was associated with higher pathologic stage and LVI in MIBC patients who underwent radical cystectomy [ 28 ]. This finding strongly implies UC with micropapillary variant presents higher capability of invasion and metastasis.…”

Section: Discussionmentioning

confidence: 99%

Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies

Miyake

Nishimura

Fujii

et al. 2021

Cancers

View full text Add to dashboard Cite

The 2016 World Health Organization classification newly described infiltrating urothelial carcinoma (UC) with divergent differentiation (DD) or variant morphologies (VMs). Data comparing oncological outcomes after bladder-preservation therapy using intravesical Bacillus Calmette–Guérin (BCG) treatment among T1 bladder pure UC (pUC), UC with DD (UC-DD), and UC with VMs (UC-VM) are limited. We evaluated 1490 patients with T1 high-grade bladder UC who received intravesical BCG during 2000–2019. They were classified into three groups: 93.6% with pUC, 4.4% with UC-DD, and 2.0% with UC-VM. Recurrence-free, progression-free, and cancer-specific survival following intravesical BCG were compared among the groups using multivariate Cox regression analysis, also used to estimate inverse probability of treatment weighting-adjusted hazard ratio and 95% confidence interval for the outcomes. Glandular differentiation and micropapillary variant were the most common forms in the UC-DD and UC-VM groups, respectively. Of 1490 patients, 31% and 13% experienced recurrence and progression, respectively, and 5.0% died of bladder cancer. Survival analyses revealed the impact of concomitant VMs was significant for cancer-specific survival, but not recurrence-free and progression-free survival compared with that of pUC. Our analysis clearly demonstrated that concomitant VMs were associated with aggressive behavior in contrast to concomitant DD in patients treated with intravesical BCG.

show abstract

Section: Discussionmentioning

confidence: 99%

Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies

Miyake

Nishimura

Fujii

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Similarly, Fairey et al compared the outcomes of 33 patients with micropapillary variant to 1347 with PUC, and found that although micropapillary variant was associated with several adverse pathological features (higher stage, grade, and tumour multifocality), there was no difference in OS or recurrence‐free survival at 5 years. Mitra et al also looked at micropapillary variant and found in comparison with PUC that patients with micropapillary variant had poorer 5‐year recurrence‐free survival (70% vs 44%, P < 0.01) and OS (61% vs 38%, P < 0.01). This was not found to be significant on multivariate analysis for risks of recurrence ( P = 0.27) or mortality ( P = 0.12).…”

Section: Discussionmentioning

confidence: 99%

The impact of non‐urothelial variant histology on oncological outcomes following radical cystectomy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Subcategories of variant histology were not examined in detail as they comprised a small minority of the population and this was beyond the analytic scope; outcomes of these subgroups have been characterized previously. 29,30 This population also predates the increasing use of immune checkpoint inhibitors and other targeted therapies for advanced UCB management. The strength of this study rests on the well-curated clinical information on patients with UCB undergoing RC from a prospectively maintained database.…”

Section: Discussionmentioning

confidence: 99%

Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases

et al. 2022

Self Cite

View full text Add to dashboard Cite

Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation

Cited by 22 publications

References 29 publications

Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies

Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies

The impact of non‐urothelial variant histology on oncological outcomes following radical cystectomy

Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases

Contact Info

Product

Resources

About